Structure Issuance Of Capital Stock from 2010 to 2024

GPCR Stock   33.41  3.31  11.00%   
Structure Therapeutics Issuance Of Capital Stock yearly trend continues to be relatively stable with very little volatility. Issuance Of Capital Stock is likely to grow to about 495.9 M this year. During the period from 2010 to 2024, Structure Therapeutics Issuance Of Capital Stock destribution of quarterly values had range of 495.9 M from its regression line and mean deviation of  111,314,785. View All Fundamentals
 
Issuance Of Capital Stock  
First Reported
2010-12-31
Previous Quarter
472.3 M
Current Value
495.9 M
Quarterly Volatility
169.7 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Structure Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Structure Therapeutics' main balance sheet or income statement drivers, such as Tax Provision of 247.8 K, Net Interest Income of 14.1 M or Depreciation And Amortization of 241.8 K, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 3.47. Structure financial statements analysis is a perfect complement when working with Structure Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Structure Therapeutics Correlation against competitors.

Latest Structure Therapeutics' Issuance Of Capital Stock Growth Pattern

Below is the plot of the Issuance Of Capital Stock of Structure Therapeutics American over the last few years. It is Structure Therapeutics' Issuance Of Capital Stock historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Structure Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Issuance Of Capital Stock10 Years Trend
Slightly volatile
   Issuance Of Capital Stock   
       Timeline  

Structure Issuance Of Capital Stock Regression Statistics

Arithmetic Mean66,672,958
Geometric Mean168,965
Coefficient Of Variation254.57
Mean Deviation111,314,785
Median25,837
Standard Deviation169,727,524
Sample Variance28807.4T
Range495.9M
R-Value0.61
Mean Square Error19549.8T
R-Squared0.37
Significance0.02
Slope23,080,345
Total Sum of Squares403304.1T

Structure Issuance Of Capital Stock History

2024495.9 M
2023472.3 M
202231.5 M
2021103.4 K

About Structure Therapeutics Financial Statements

Structure Therapeutics shareholders use historical fundamental indicators, such as Issuance Of Capital Stock, to determine how well the company is positioned to perform in the future. Although Structure Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Structure Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Structure Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Issuance Of Capital Stock472.3 M495.9 M

Pair Trading with Structure Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Structure Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Structure Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving together with Structure Stock

  0.64A Agilent Technologies Earnings Call This WeekPairCorr
  0.71ME 23Andme HoldingPairCorr

Moving against Structure Stock

  0.43MDGL Madrigal PharmaceuticalsPairCorr
  0.43KEP Korea Electric PowerPairCorr
  0.31RNXT RenovoRxPairCorr
The ability to find closely correlated positions to Structure Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Structure Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Structure Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Structure Therapeutics American to buy it.
The correlation of Structure Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Structure Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Structure Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Structure Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Additional Tools for Structure Stock Analysis

When running Structure Therapeutics' price analysis, check to measure Structure Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Structure Therapeutics is operating at the current time. Most of Structure Therapeutics' value examination focuses on studying past and present price action to predict the probability of Structure Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Structure Therapeutics' price. Additionally, you may evaluate how the addition of Structure Therapeutics to your portfolios can decrease your overall portfolio volatility.